Integrated Filing — IndAS



General information about company

Scrip Code 539524
NSE Symbol LALPATHLAB
MSEI Symbol NOTLISTED
ISIN INE600L01024
Name of company Dr. Lal Path Labs Ltd.
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-04-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.
Start date and time of board meeting 30-04-2026   11:30:00
End date and time of board meeting 30-04-2026   15:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 30-01-2026
Indicate Company website link for updated RPT policy of the Company https://media.lalpathlabs.com/2026-02/e2734ad1-6dc6-4e03-991d-62ad36076310.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 67,520.00 2,64,760.00
Other income 3,700.00 11,270.00
Total income 71,220.00 2,76,030.00
2 Expenses
(a) Cost of materials consumed 12,890.00 50,800.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 12,140.00 47,520.00
(e) Finance costs 590.00 2,200.00
(f) Depreciation, depletion and amortisation expense 4,270.00 15,410.00
(f) Other Expenses
1 Fees to collection centers/channel partners 9,880.00 39,480.00
2 Other expenses 14,460.00 51,590.00
Total other expenses 24,340.00 91,070.00
Total expenses 54,230.00 2,07,000.00
3 Total profit before exceptional items and tax 16,990.00 69,030.00
4 Exceptional items 0.00 (3,010.00)
5 Total profit before tax 16,990.00 66,020.00
6 Tax expense
7 Current tax 2,730.00 15,060.00
8 Deferred tax 150.00 140.00
9 Total tax expenses 2,880.00 15,200.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 14,110.00 50,820.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 14,110.00 50,820.00
17 Other comprehensive income net of taxes 430.00 500.00
18 Total Comprehensive Income for the period 14,540.00 51,320.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,760.00 16,760.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 2,30,530.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 8.45 30.45
Diluted earnings (loss) per share from continuing operations 8.44 30.4
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 8.45 30.45
Diluted earnings (loss) per share from continuing and discontinued operations 8.44 30.4
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 April, 2026. The financial results for the year ended 31 March, 2026 have been audited and for the quarter ended 31 March, 2026 have been reviewed by the statutory auditors of the Company and they have issued an unmodified report thereon. ii. These financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS)prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. iii. Figures for the quarter ended 31 March, 2026 and 31 March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2025 and 31 December, 2024 respectively, which were subjected to limited review. iv. During the year ended 31 March 2026, the Company has issued 4,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options. Further, during the year ended 31 March 2026, the Company has issued 183,775 equity shares of face value of Rs. 10 each , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 (ESOP Plan, 2022). v. The Board of Directors of the Company at their meeting held on 30 April 2026 has proposed final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The total dividend for the year including the final dividend (subject to the approval of shareholders at the ensuing Annual General Meeting) is INR 20.5 per equity share having face value of INR 10 each. The Board of Directors of the Company had approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026 and this was paid on 16 February,2026. The Board of Directors of the Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 and this was paid on 17 November, 2025. The Board of Directors of the Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 and this was paid on 14 August, 2025. The Board of Directors of the Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. vi.During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, has been dissolved and its name has been struck off, with effect from the date of publication of gazette notification dated September 13, 2024. vii. The Board of the Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited (SDIPL), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. The Hon’ble National Company Law Tribunal (“NCLT”), Mumbai Bench vide its order dated February 27, 2026, approved dissolution of SDIPL. The said distribution of business undertaking has been accounted for using the pooling of interests method in accordance with Appendix C of Ind AS 103 ‘Business combinations of entities under common control’. Accordingly, the comparative financial information for the previous periods have been restated to give effect of the consummation of business undertaking from beginning of the period disclosed and all assets, liabilities and reserves of SDIPL together with intangible assets – long term service agreements and related deferred tax liability has been recognised in the Standalone Financial Statement. The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year end 31 March, 2025. viii. The shareholders of the Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter March 31, 2025 and year ended March 31, 2025 have been restated to give effect to the allotment of the bonus shares. ix. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Standalone Statement of Profit and Loss for the three months ended December 31, 2025. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. x. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. xi. During the year, the company has regrouped manpower cost aggregating to INR 264 million for the year ended 31 March, 2025, INR 79 million for quarter ended 31 December 2025, INR 69 million for the quarter ended 31 March 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract. xii. Refer Annexure A for Statement of Standalone Assets and Liabilities and Annexure B for Standalone Cash Flow Statement.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 46,940.00
Capital work-in-progress 550.00
Investment property 3,280.00
Goodwill 47,110.00
Other intangible assets 16,990.00
Intangible assets under development 100.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 11,390.00
Trade receivables, non-current 0.00
Loans, non-current 10.00
Other non-current financial assets
1 Other financial assets 19,290.00
Total of other non-current financial assets 19,290.00
Total non-current financial assets 30,690.00
Deferred tax assets (net) 8,150.00
Other non-current assets
1 Non-current tax assets (net) 1,590.00
2 Other non-current assets 60.00
Total of other non-current assets 1,650.00
Total non-current assets 1,55,460.00
2 Current assets
Inventories 4,060.00
Current financial asset
Current investments 39,930.00
Trade receivables, current 13,420.00
Cash and cash equivalents 23,440.00
Bank balance other than cash and cash equivalents 60,940.00
Loans, current 170.00
Other current financial assets
Total of other current financial assets 5,350.00
Total current financial assets 1,43,250.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,150.00
Total of other current assets 2,150.00
Total current assets 1,49,460.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,04,920.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,760.00
Other equity 2,30,530.00
Total equity attributable to owners of parent 2,47,290.00
Non controlling interest
Total equity 2,47,290.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 14,190.00
Total of other non-current financial liabilities 14,190.00
Total non-current financial liabilities 14,190.00
Provisions, non-current 0.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 14,190.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,680.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 15,910.00
Total Trade payable 17,590.00
Other current financial liabilities
1 Other financial liabilities 8,960.00
2 Lease liabilities 5,100.00
Total of other current financial liabilities 14,060.00
Total current financial liabilities 31,650.00
Other current liabilities 3,920.00
1 Other current liabilities 3,920.00
Total of other current liabilities 3,920.00
Provisions, current 7,180.00
Current tax liabilities (Net) 690.00
Deferred government grants, Current 0.00
Total current liabilities 43,440.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 57,630.00
Total equity and liabilites 3,04,920.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the defined benefit obligations 570.00 670.00
Total Amount of items that will not be reclassified to profit and loss 570.00 670.00
2 Income tax relating to items that will not be reclassified to profit or loss 140.00 170.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 430.00 500.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 66,020.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,200.00
Adjustments for decrease (increase) in inventories (830.00)
Adjustments for decrease (increase) in trade receivables, current (3,310.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 30.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (270.00)
Adjustments for other financial assets, current (80.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,310.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (130.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 15,410.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 4,480.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 500.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 1,890.00
Adjustments for interest income 6,160.00
Adjustments for share-based payments 2,380.00
Adjustments for fair value losses (gains) (2,570.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (340.00)
Other adjustments to reconcile profit (loss) 500.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 11,230.00
Net cash flows from (used in) operations 77,250.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 16,660.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 60,590.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 50.00
Purchase of property, plant and equipment 16,440.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 620.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 1,890.00
Interest received 6,090.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (29,180.00)
Net cash flows from (used in) investing activities (38,210.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 1,860.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 3,550.00
Dividends paid 21,700.00
Interest paid 2,210.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (25,600.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (3,220.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (3,220.00)
Cash and cash equivalents cash flow statement at beginning of period 26,660.00
Cash and cash equivalents cash flow statement at end of period 23,440.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells LLP Yes 31-07-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dr. Lal Pathlabs Limited Paliwal Diagnostics Private Limited Subsidairy Sale of goods or services 127.30 NA 127.30 0.00 0.00
2 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Nepal Private Limited Wholly Owned Subsidiary Sale of goods or services 301.70 NA 301.70 1,224.70 1,287.10
3 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Bangladesh Private Limited Subsidairy Sale of goods or services 223.30 NA 223.30 1,517.70 1,741.00
4 Dr. Lal Pathlabs Limited Pathlabs Unifiers Private Limited Wholly Owned Subsidiary Sale of goods or services 23.00 NA 23.00 0.00 0.00
5 Dr. Lal Pathlabs Limited APRL PathLabs Private Limited Subsidairy Sale of goods or services 23.50 NA 23.50 0.00 0.00
6 Dr. Lal Pathlabs Limited Centrapath Labs Private Limited Subsidairy Sale of goods or services 20.60 NA 20.60 0.00 0.00
7 Dr. Lal Pathlabs Limited Dr. Lal Ventures Private Limited Wholly Owned Subsidiary Sale of goods or services 47.90 NA 47.90 0.00 8.40
8 Dr. Lal Pathlabs Limited Chanre Laboratory Private Limited Subsidairy Sale of goods or services 18.80 NA 18.80 0.00 0.00
9 Dr. Lal Pathlabs Limited APRL PathLabs Private Limited Subsidairy Purchase of goods or services 107.30 NA 107.30 0.00 0.00
10 Dr. Lal Pathlabs Limited Centrapath Labs Private Limited Subsidairy Purchase of goods or services 158.30 NA 158.30 0.00 0.00
11 Dr. Lal Pathlabs Limited Chanre Laboratory Private Limited Subsidairy Purchase of goods or services 24.20 NA 24.20 0.00 0.00
12 Dr. Lal Pathlabs Limited Paliwal Diagnostics Private Limited Subsidairy Purchase of goods or services 0.50 NA 0.50 0.00 0.00
13 Dr. Lal Pathlabs Limited Dr. Vandana Lal Key Management Personnel and its relatives Remuneration 162.00 NA 162.00 0.00 0.00
14 Dr. Lal Pathlabs Limited (Hony) Brig. Dr. Arvind Lal Key Management Personnel and its relatives Remuneration 201.90 NA 201.90 0.00 0.00
15 Dr. Lal Pathlabs Limited Anjaneya Lal Key Management Personnel and its relatives Remuneration 18.00 NA 18.00 0.00 0.00
16 Dr. Lal Pathlabs Limited Dr. Vandana Lal Key Management Personnel and its relatives Any other transaction Rent 4.30 NA 4.30 0.00 0.00
17 Dr. Lal Pathlabs Limited Dr. Archana Lal Erdmann Key Management Personnel and its relatives Any other transaction Sitting fees and Director Commission 21.90 NA 21.90 0.00 0.00
18 Dr. Lal Pathlabs Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Contribution towards CSR activity 536.10 NA 536.10 0.00 0.00
19 Dr. Lal Pathlabs Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Corpus NA 0.00 1.00 1.00
20 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Limited Group Gratuity Trust Entities with joint control or significant influence over entity Any other transaction Corpus NA 0.00 1.40 1.40
21 Dr. Lal Pathlabs Limited ALVL Foundation Entities with joint control or significant influence over entity Sale of goods or services 3.20 NA 3.20 0.00 0.00
22 Dr. Lal Pathlabs Limited Rahul Sharma Key Management Personnel and its relatives Any other transaction Amount received for Issue of equity shares 6.20 NA 6.20 0.00 0.00
23 Dr. Lal Pathlabs Limited Rahul Sharma Key Management Personnel and its relatives Any other transaction Share based compensation perk 49.70 NA 49.70 0.00 0.00
24 Paliwal Diagnostics Private Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Contribution towards CSR activity 13.70 NA 13.70 0.00 0.00
25 Pathlabs Unifiers Private Limited APRL PathLabs Private Limited Subsidairy Purchase of goods or services 1.30 NA 1.30 0.00 0.00
26 APRL PathLabs Private Limited Dr. Subhash Padmani Key Management Personnel and its relatives Remuneration 14.00 NA 14.00 0.00 0.00
27 APRL PathLabs Private Limited Dr. Ripal Padmani Key Management Personnel and its relatives Any other transaction Retainership Fees 6.00 NA 6.00 0.00 0.00
28 Centrapath Labs Private Limited Dr. Vineeta Kothari Key Management Personnel and its relatives Remuneration 20.00 NA 20.00 0.00 0.00
29 Centrapath Labs Private Limited Dr. Vineeta Kothari Key Management Personnel and its relatives Any other transaction Rent NA 4.50 0.00 0.00
30 Chanre Laboratory Private Limited Dr. Renuka Chandrasekhar Key Management Personnel and its relatives Remuneration 22.00 NA 22.00 0.00 0.00
31 Chanre Laboratory Private Limited Dr. Renuka Chandrasekhar Key Management Personnel and its relatives Any other transaction Rent NA 16.70 0.00 0.00
32 Chanre Laboratory Private Limited Chanre Rheumatology and Immunologycenter and Research Private Limited Entities with joint control or significant influence over entity Sale of goods or services 250.80 NA 250.80 0.00 0.00
33 Paliwal Diagnostics Pvt Ltd Dr. Umesh Paliwal Key Management Personnel and its relatives Any other transaction Rent NA 71.70 0.00 0.00
34 Paliwal Diagnostics Pvt Ltd Dr. Umesh Paliwal Key Management Personnel and its relatives Any other transaction Retainership Fees 27.20 NA 27.20 0.00 0.00
35 Paliwal Diagnostics Pvt Ltd Dr. Mridula Paliwal Key Management Personnel and its relatives Any other transaction Retainership Fees 13.60 NA 13.60 0.00 0.00
36 Paliwal Diagnostics Pvt Ltd Mrs. Arushi Paliwal Key Management Personnel and its relatives Any other transaction Rent NA 0.60 0.00 0.00
37 Centrapath Labs Private Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Contribution towards CSR activity 11.40 NA 11.40 0.00 0.00
38 Centrapath Labs Private Limited Sushila Dalal Key Management Personnel and its relatives Any other transaction Rent 9.90 NA 9.90 0.00 0.00
Total value of transaction during the reporting period 2,563.10